A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.
Novo Nordisk said that patients taking a higher dose of its blockbuster obesity drug Wegovy lost more weight than those on a lower dose without experiencing an increase in side-effects ...
Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback